How should we initiate bridging from a heparin infusion back to warfarin in a patient with atrial fibrillation and antiphospholipid antibody syndrome who requires a target INR of 2.5–3.5?

Bridging from Heparin to Warfarin in High-Risk AF with Antiphospholipid Antibody Syndrome

Continue the heparin infusion and start warfarin immediately, overlapping both agents for at least 5 days AND until the INR reaches 2.5-3.5 for at least 24 hours on two consecutive measurements before discontinuing heparin.

Initiation Protocol

Start Warfarin While on Heparin

• Begin warfarin at your institution's standard loading dose (typically 5-10 mg, adjusted for age/body size) while maintaining therapeutic heparin infusion 1
• Do not stop or taper the heparin when starting warfarin—full overlap is essential 2, 3

Target INR for This Patient

Given the combination of atrial fibrillation AND antiphospholipid antibody syndrome, your target INR is 2.5-3.5 (higher than standard AF alone) 4. The antiphospholipid syndrome increases thrombotic risk substantially and warrants the higher target range, particularly with documented high clot risk.

Monitoring During Bridge

Check INR daily during the initiation phase 5:

• Continue heparin with aPTT monitoring (goal 1.5-2 times control) 3, 2, 1
• Adjust warfarin dose based on INR response
• Critical point: The INR will start rising within 2-3 days, but this reflects depletion of Factor VII (short half-life), NOT adequate anticoagulation—you need at least 5 days for Factor II depletion

When to Stop Heparin

Discontinue heparin only when ALL of the following are met 1:

1. Minimum 5 days of overlap with warfarin
2. INR is therapeutic (2.5-3.5) for at least 24 hours
3. Two consecutive therapeutic INR measurements to confirm stability

The FDA label explicitly states: "continue full heparin therapy for several days until the INR has reached a stable therapeutic range" 1. Do not stop heparin prematurely based on a single therapeutic INR—this is a common pitfall that leads to thrombotic events.

Special Considerations for Antiphospholipid Antibody Syndrome

Why This Patient Needs Extra Caution

Patients with antiphospholipid syndrome have:

• Higher recurrent thrombosis rates than standard AF patients 6, 7
• Potential lupus anticoagulant interference with aPTT monitoring 8—if aPTT is prolonged at baseline, consider anti-Xa levels to monitor heparin (goal 0.3-0.7 units/mL for therapeutic dosing)
• Increased risk during the warfarin initiation period when protein C/S levels drop before full anticoagulation is achieved

DOACs Are NOT an Option Here

Do not use direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) in patients with antiphospholipid syndrome 4, 5. The 2021 CHEST guidelines specifically recommend against DOACs in confirmed antiphospholipid syndrome, particularly in triple-positive patients, due to increased thrombotic events compared to warfarin 4. Warfarin remains the gold standard.

Post-Discharge Monitoring

Once heparin is discontinued and the patient is on warfarin alone:

• Check INR 2-3 times weekly for 1-2 weeks 5
• Then weekly for 1 month if stable 9
• Then every 2-4 weeks once consistently therapeutic 10

More frequent monitoring is needed if:

• Dietary changes occur
• New medications are started
• Intercurrent illness develops
• Any bleeding signs appear

Common Pitfalls to Avoid

1. Stopping heparin too early: A single therapeutic INR after 2-3 days is insufficient—you need 5+ days overlap AND stable therapeutic levels
2. Using standard AF target (2.0-3.0): This patient needs 2.5-3.5 due to antiphospholipid syndrome
3. Considering DOACs: These are contraindicated in antiphospholipid syndrome
4. Ignoring lupus anticoagulant effects on aPTT: If baseline aPTT is elevated, switch to anti-Xa monitoring for heparin

The key principle: maintain full therapeutic anticoagulation throughout the entire transition period without any gaps in coverage 3, 2, 3.